CBD Life Sciences(CBDL)
$0.000.00 (0.00%)
CBDL
CBD Life Sciences financials statements
$0.00
At close:0.00 (0.00%)
CBD Life Sciences (CBDL) Ratios
135 Followers
CBD Life Sciences Ratios
CBDL's free cash flow for Q2 2026 was $42.85K. For the 2026 fiscal year, CBDL's free cash flow was decreased by $-2.38K and operating cash flow was $45.23K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 15.12 | 17.18 | 8.06 | 0.00 | 0.00 |
| Quick Ratio | 14.21 | 14.93 | 7.21 | 0.00 | 0.00 |
| Cash Ratio | 8.61 | 0.46 | 0.10 | 0.00 | 0.00 |
| Solvency Ratio | -1.27 | -49.65 | -0.93 | 0.00 | -160.94 |
| Operating Cash Flow Ratio | -3.61 | -41.26 | -0.67 | 0.00 | 0.00 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 543.85K | $ 228.69K | $ 174.58K | $ 178.01K | $ 1.04M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.04 | 1.06 | 1.00 | 1.02 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 3.26 | 0.01 | 0.11 | 0.00 | 0.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 42.20% | -9.08% | -18.31% | -174.90% | -250.18% |
| EBIT Margin | -103.44% | -695.36% | -47.01% | -536.57% | -8654.24% |
| EBITDA Margin | -103.44% | -644.34% | -13.77% | -503.15% | -8255.03% |
| Operating Profit Margin | -103.44% | -695.36% | -47.01% | -536.57% | -8654.23% |
| Pretax Profit Margin | -49.76% | -695.36% | -47.01% | -536.57% | -8654.24% |
| Net Profit Margin | -49.76% | -695.36% | -47.01% | -536.57% | -8654.24% |
| Continuous Operations Profit Margin | -49.76% | -695.36% | -47.01% | -536.57% | -8654.24% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 48.11% | 100.00% | 100.00% | 100.00% | 100.00% |
| Return on Assets (ROA) | -6.08% | -186.16% | -18.74% | -181.72% | -376.15% |
| Return on Equity (ROE) | -6.38% | -192.86% | -19.91% | -181.72% | -384.73% |
| Return on Capital Employed (ROCE) | -13.26% | -192.86% | -19.91% | -181.72% | -376.15% |
| Return on Invested Capital (ROIC) | -13.26% | -192.86% | -19.91% | -181.72% | -376.15% |
| Return on Tangible Assets | -6.94% | -254.74% | -26.82% | -230.41% | -376.18% |
| Earnings Yield | -5.95% | -48.89% | -0.02% | -0.00% | -0.04% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.46 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.70 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 1.62 | 3.73 | 9.50 | 54.25 | 0.00 |
| Fixed Asset Turnover | 0.00 | 3.45 | 1.88 | 0.84 | 0.39 |
| Asset Turnover | 0.12 | 0.27 | 0.40 | 0.34 | 0.04 |
| Working Capital Turnover Ratio | 0.25 | 0.54 | 0.95 | 0.26 | 0.11 |
| Cash Conversion Cycle | 811.50 | 97.73 | 38.44 | 6.73 | 0.00 |
| Days of Sales Outstanding | 800.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 225.26 | 97.73 | 38.44 | 6.73 | 0.00 |
| Days of Payables Outstanding | 214.46 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 1025.96 | 97.73 | 38.44 | 6.73 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Free Cash Flow Per Share | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -194359.00 | 0.00 | -13.87 | -31.86 |
| Capital Expenditure Coverage Ratio | 0.00 | -194359.00 | 0.00 | -13.87 | -31.86 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | -1.42 | -5.35 | -0.10 | -5.97 | -86.87 |
| Free Cash Flow Yield | -16.93% | -37.65% | 0.00% | -0.00% | -0.04% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -16.80 | -2.05 | -5180.62 | -47343.63 | -2397.98 |
| Price-to-Sales (P/S) Ratio | 8.36 | 14.22 | 2435.36 | 254031.37 | 207526.68 |
| Price-to-Book (P/B) Ratio | 1.07 | 3.94 | 1031.62 | 86030.97 | 9225.63 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.91 | -2.66 | 207897.04 | -39662.41 | -2316.29 |
| Price-to-Operating Cash Flow Ratio | -5.91 | -2.66 | -24464.36 | -42521.13 | -2388.99 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | 0.03 | -25.90 | 946.87 | 30.83 |
| Enterprise Value Multiple | -4.82 | -2.20 | -17685.18 | -50488.49 | -2513.73 |
| Enterprise Value | 490.40K | 1.54M | 407.06M | 40.71B | 12.30B |
| EV to EBITDA | -4.82 | -2.20 | -17685.18 | -50488.49 | -2513.73 |
| EV to Sales | 4.99 | 14.16 | 2435.34 | 254031.37 | 207509.36 |
| EV to Free Cash Flow | -3.52 | -2.64 | 207895.76 | -39662.41 | -2316.10 |
| EV to Operating Cash Flow | -3.52 | -2.64 | -24464.20 | -42521.13 | -2388.79 |
| Tangible Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.48 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.46 | 6.86 | 0.18 | 1.04 | 23.38 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.84 | 0.77 | 0.21 | 1.11 | 1.00 |
Currency in USD
